[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interstitial-lung-disease-due-to-systemic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interstitial-lung-disease-due-to-systemic-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,39,73,99,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100053893","the-kings-brief-lnterstitial-lung-disease-questionnaire-100053893",false,"NCT07700004","The King's Brief Lnterstitial Lung Disease Questionnaire","Investigation of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals With Interstitial Lung Involvement Secondary to Rheumatological Diseases","Inclusion Criteria:-Having been diagnosed with interstitial lung disease by a rheumatologist,\n\n* Being 18 years of age or older,\n* Agreeing to participate in the study.\n\nExclusion Criteria:- Presence of a neurological disease\n\n* Presence of any orthopedic problem that affects functionality\n* History of any orthopedic surgery in the last year\n* Inability to speak or understand Turkish fluently\n* Presence of a psychiatric illness that affects cooperation\n* Heart failure that affects daily living activities\n* Being a cancer patient","ALL","18 Years",{"count":19,"type":20},45,"ESTIMATED","1 Day","OBSERVATIONAL","The aim of this study is to examine the validity and reliability of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals with Interstitial Lung Involvement Secondary to Rheumatological Diseases.",[25],"Interstitial Lung Disease Due to Systemic Disease","NOT_YET_RECRUITING","2026-07-07",{"date":29,"type":30},"2026-07-13","ACTUAL",{"date":32,"type":20},"2026-07-05",{"date":34,"type":20},"2027-05-15",{"name":36,"class":37},"Pamukkale University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100531075","phase-2-platform-clinical-study-for-conquering-scleroderma-100531075","NCT06195072","Platform Clinical Study for Conquering Scleroderma","Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants With Interstitial Lung Disease Secondary to Systemic Sclerosis","CONQUEST","Inclusion Criteria:\n\n1. Male or female 18+ years of age at the time of signed informed consent;\n2. SSc classification as defined by the 2013 American College of Rheumatology\u002FEuropean League Against Rheumatism criteria. Participants with diffuse, limited or sine cutaneous skin involvement are eligible\n3. Onset of SSc (defined by first non-Raynaud's symptom) 7 years or less prior to the Screening Visit;\n4. A Modified Rodnan skin score (mRSS) less than 40\n5. Presence of ILD with evidence of any fibrosis on HRCT (within 3 months or less of randomization)\n6. Presence of an FVC 45% or more predicted normal;\n7. Presence of a diffusing capacity of the lung for carbon monoxide (DLCO) 30% or more predicted normal, corrected for hemoglobin;\n\nOther protocol and\u002For subprotocol inclusion criteria apply.\n\nExclusion Criteria:\n\n1. Presence of clinically significant pulmonary abnormalities inconsistent with ILD on HRCT (e.g., scarring due to previous active tuberculosis \\[TB\\], sarcoidosis, lung mass, or other findings unrelated to SSc-ILD, as determined by a local radiologist\u002FInvestigator);\n2. Presence of infected ulcers or active gangrene at the Screening Visit;\n3. History of scleroderma renal crisis within 6 months prior to the Screening Visit;\n4. Forced expiratory volume in 1 second\u002FFVC \\\u003C0.65 (pre-bronchodilator) at the Screening Visit\n5. History of stem cell transplantation, bone marrow transplantation, chimeric antigen receptor T-cell therapy, or solid organ transplantation;\n6. History of treatment with rituximab within the 6 months prior to the Screening Visit;\n7. History treatment with cell-depleting therapies other than rituximab, including, but not limited to, CAMPATH®; anti-cluster of differentiation (CD)3, anti-CD4, anti-CD5, antiCD19, and anti-CD20 agents; and investigational agents\n8. Treatment with tocilizumab, nintedanib, pirfenidone, abatacept, leflunomide, tacrolimus, tofacitinib, intravenous immunoglobulin (IVIG), or any biologic or cyclophosphamide within 3 months prior to Screening Visit\n9. History of use of any investigational medication or device for any indication within 30 days or 5 half-lives (whichever is longer) prior to Screening Visit.\n10. Presence of any of the following laboratory findings at the Screening Visit:\n\n    * Estimated glomerular filtration rate \\\u003C45 mL\u002Fmin\u002F1.73 m2, calculated using the Chronic Kidney Disease Epidemiology Collaboration equation;\n    * Alanine aminotransferase or aspartate aminotransferase level \\> (2 x ULN);\n    * Platelets \\\u003C100 × 109\u002FL (100,000\u002FμL);\n    * White blood cell count \\\u003C2500\u002FμL;\n    * Neutrophil blood count \\\u003C1500\u002FμL;\n    * Prothrombin time and partial thromboplastin time \\>1.5 × ULN, or international normalized ratio \\>2; or\n    * Any other laboratory test result, that in the opinion of the Investigator, might place the study participant at risk for participation in the study.\n11. Presence of a clinically significant disorder that, in the opinion of the Investigator, could contraindicate the administration of study product, affect compliance, interfere with study evaluations, or confound the interpretation of study results\n12. Presence of a concomitant life-threatening disease with life expectancy \\\u003C12 months based on the Investigator's assessment;\n13. Evidence of active tuberculosis (TB) or being at high risk for TB\n\nOther protocol and\u002For subprotocol exclusion criteria apply.",{"count":48,"type":20},400,"INTERVENTIONAL",[51],"PHASE2","The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.",[25,54],"Scleroderma",[56,57,58,59,60,61],"platform","scleroderma","interstitial lung disease","systemic sclerosis","SSc","SSc-ILD","RECRUITING","2026-02-02",{"date":65,"type":30},"2026-02-04",{"date":67,"type":30},"2024-04-15",{"date":69,"type":20},"2026-11",{"name":71,"class":37},"Scleroderma Research Foundation, Inc.",34,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":38},"100619471","western-sweden-systemic-sclerosis-project-100619471","NCT07345052","Western Sweden Systemic Sclerosis Project","Western Sweden Systemic Sclerosis Project - A Study on Underlying Mechanisms for Disease Development and Predictors of Disease Activity and Treatment Response in Patients With Systemic Sclerosis","WESST","Inclusion Criteria:\n\n* Participants diagnosed with SSc according to the ACR and EULAR classification criteria\n\nExclusion Criteria:\n\n* Diagnosis of Mixed connective tissue disease\n* Not speaking or reading Swedish\n* With severe cognitive impairment\n* With blood count below specified limits\n* Allergy to local anaesthetic (for subjects who will provide a skin biopsy)",true,{"count":83,"type":20},150,"5 Years","The main aim of the project is to identify key-factors involved in the development and progression of Systemic Sclerosis (SSc), a chronic invalidating rheumatic disease characterized by high mortality and insufficient treatment options. A cohort of patients with SSc will be collected at the Sahlgrenska University Hospital in Gothenburg, Skaraborg Hospital in Skövde, and Södra Älvsborg Hospital in Borås (Sweden). Thanks to a holistic approach including integrated analysis of blood, and skin samples as well as DNA, and with the use of state-of-the-art methods, this project aims to identify factors (e.g. genes, proteins, metabolites, and immune cell types) associated with the development of SSc and with the progression to a more aggressive phenotype. Functional studies using in vitro model systems and patient specimens will be also implemented. The findings of the current project could lead to the identification of possible diagnostic and prognostic markers for the disease as well as potential drug targets. This cohort will be also linked to the European Scleroderma Trial and Research (EUSTAR), which is an international SSc research network aiming to coordinate research activities on SSc from groups all over Europe in order to improve treatment, quality of life and mortality of patients with SSc.",[87,88,89,25],"Scleroderma, Systemic","Fibrosis; Skin","Fibrosis Lung","2026-01-07",{"date":92,"type":30},"2026-01-15",{"date":94,"type":30},"2022-06-20",{"date":96,"type":20},"2030-12-31",{"name":98,"class":37},"Sahlgrenska University Hospital",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":38},"100609631","teleconsultation-approach-to-ctd-ild-care-delivery-in-rural-underserved-communities-trust-initiative-100609631","NCT07217093","Teleconsultation Approach to CTD-ILD Care Delivery in Rural UnderServed CommuniTies (TRUST Initiative)","Inclusion Criteria:\n\n1. Age: Adults aged 18 years or older.\n2. Diagnosis and Stable Condition:\n\n   * Confirmed diagnosis of connective tissue disease-associated interstitial lung disease (CTD-ILD) by a physician based on clinical, radiographic, and\u002For pathological criteria. CTDs may include scleroderma, systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, Sjogren's disease (primary or secondary), inflammatory myopathy including but not limited to dermatomyositis and polymyositis, or any overlap syndrome including one or more of these diseases.\n   * Diagnosis of CTD-ILD established at least one year prior to enrollment\n3. Residence:\n\n   * Full time resident (at least six months per year) of one of the seven counties of the North Country region of New York (St. Lawrence, Franklin, Jefferson, Lewis, Hamilton, Clinton, Essex)\n4. Active Care Relationship:\n\n   * Documented diagnosis of CTD-ILD via any of the following:\n\n     o SLH-affiliated clinician\n\n     o Historical records\n     * Determination by PI\n   * Or an active SLH medical record (≥1 clinical encounter, test, or treatment in past 24 months)\n5. Pulmonary Function Testing and safety labs:\n\n   * Ability and willingness to perform pulmonary function and safety lab tests at local facilities as required by the study protocol.\n   * Most recent PFT within 24 months prior to baseline\n6. Consent:\n\n   * Provide written informed consent to participate in the study, including consent for data collection and telehealth consultations.\n\n8\\. Contraception\n\n\\- Female patients of child-bearing potential (FOCBP) must use at least one highly effective method of contraception between weeks 0 and 48 of the study (complete abstinence, estrogen+progesterone oral contraceptive pill (OCP), progestin-only pill (POP), estrogen+progesterone patch, vaginal ring, Nexplanon, DepoProvera, IUD, bilateral tubal ligation, male partner vasectomy completed at least six months prior to Day 0).\n\nThese inclusion criteria ensure that participants are appropriately diagnosed and can engage fully with the teleconsultation-based care model while addressing the program's focus on improving access for rural and other under-resourced populations.\n\nExclusion Criteria:\n\n1\\. Severe Cognitive or Mental Health Impairment:\n\n* Individuals with severe cognitive dysfunction or mental health conditions that, in the judgment of the PI, would interfere with the ability to provide informed consent or participate in teleconsultation sessions.\n\n  2\\. Life Expectancy \\\u003C 6 Months:\n* Participants with a life expectancy of less than six months due to any cause, as determined by the PI.\n\n  3\\. Other Severe Pulmonary Diseases:\n* Individuals with other severe pulmonary conditions determined by PI with input from Sub-Is (e.g., chronic obstructive pulmonary disease \\[COPD\\], pulmonary fibrosis unrelated to CTD-ILD, or active lung cancer) that may confound the assessment of CTD-ILD progression.\n\n  4\\. Inability to Perform Pulmonary Function Tests:\n* Participants who are unable to perform or complete the required pulmonary function tests because of physical limitations (e.g., significant respiratory distress or severe disability) or non-compliance.\n\n  5\\. Active Participation in another Clinical Trial:\n* Individuals currently participating in another interventional clinical trial for CTD-ILD or other chronic lung diseases that could interfere with the study outcomes.\n\n  6\\. Significant Non-Compliance Risk:\n* Participants who, in the judgment of the PI, are unlikely to comply with the study protocol or follow-up requirements (e.g., inability to attend teleconsultations, failure to complete pulmonary function tests, or non-adherence to study treatment regimen).\n\n  7\\. Current ILD Treatment:\n* Participants who are currently receiving treatment by an ILD specialist at an ILD center at an academic medical center are not eligible to participate in this study.\n\n  8\\. Pregnancy or Breastfeeding:\n* Pregnant or breastfeeding women.\n\nThese exclusion criteria are designed to ensure participant safety, minimize confounding factors, and ensure that participants are able to fully engage in the teleconsultation model and comply with study protocols.",{"count":106,"type":20},10,"Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a rare and complex condition that affects some individuals with autoimmune disorders such as rheumatoid arthritis (RA). It can lead to inflammation and progressive scarring of the lungs, significantly affecting quality of life and overall prognosis.1 Current clinical guidelines recommend that patients with CTD-ILD receive care at specialized academic medical centers with multi-disciplinary teams experienced in managing interstitial lung disease (ILD).2 These centers, however, are often located in urban areas, making access particularly challenging for patients living in rural and underserved regions. In rural, medically underserved areas, the nearest ILD centers can be three or more hours away, posing substantial barriers to timely, consistent, and expert care. These logistical constraints make it difficult for patients residing in rural areas to access the high-quality, specialized care required to manage CTD-ILD effectively.\n\nThe Teleconsultation Approach to CTD-ILD Care Delivery in Rural Underserved Communities (TRUST Initiative) it looking to address this gap in access to specialized care. The TRUST Initiative aims to evaluate whether integrating teleconsultation into a personalized, multidisciplinary care model, through regular, structured teleconsultation visits, can enhance the quality and coordination of treatment for patients and potentially other rural underserved patient populations. This model utilizes a regional rheumatologist, a regional pulmonologist and, an interstitial lung disease (ILD) specialist at the Mayo Clinic in Rochester, Minnesota.\n\nThis model seeks to overcome the geographic and logistical challenges that prevent patients from accessing specialty care. It also offers a replicable care model for managing other complex chronic diseases in underserved rural communities by leveraging collaborative care, virtual health technology, and structured communication workflows. The study will not only track clinical outcomes such as pulmonary function but also evaluate patient satisfaction, highlighting both the effectiveness and acceptability of this care model.\n\nBy addressing disparities in access to specialty care, the TRUST Initiative aims to inform future healthcare delivery strategies for rare and complex diseases in rural and underserved settings nationwide.",[109,110,25],"Interstitial Lung Disease Due to Systemic Disease (Disorder)","Interstitial Lung Disease in Patients With Rheumatoid Arthritis","2025-10-13",{"date":113,"type":30},"2025-10-15",{"date":115,"type":20},"2025-11",{"date":117,"type":20},"2026-12",{"name":119,"class":37},"St. Lawrence Health System",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":84,"studyType":22,"phases":4,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":38},"100467303","registry-of-autoimmune-interstitial-lung-disease-100467303","NCT05365009","Registry of Autoimmune Interstitial Lung Disease","Characteristics of Patients With Autoimmune Interstitial Lund Disease From Argentina","EPIMAR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Diagnosis of ILD within the last 5 years according to the criteria of the multidisciplinary team composed of at least one pulmonologist and one rheumatologist, with or without respiratory symptoms.\n* ILD defined by the presence of ground glass opacities and \u002F or peribronchovascular or airspace consolidations and \u002F or reticulations and \u002F or traction bronchiectasis and \u002F or honeycomb on high-resolution computed tomography (HRCT) within the last 12 months 17 .\n* One of the following three criteria (see annex 1):\n\nEstablished or early stage CTD 18-30. IPAF according to ATS \u002F ERS 2015 classification criteria 8 ANCA positivity by immunofluorescence confirmed by ELISA, with or without systemic vasculitis 31.\n\n* Spirometry performed within the last 6 months before entering the registry.\n* The participant must sign the informed consent voluntarily.\n\nExclusion Criteria:\n\n* Not being able to perform the clinical follow-up or the complementary studies required in the protocol.\n* Not being able to be evaluated by a multidisciplinary team; at least a rheumatologist plus a pulmonologist.\n* ILD associated with another non-autoimmune etiology according to the criteria of the multidisciplinary team (eg, occupational diseases, toxic)",{"count":129,"type":20},1000,"Interstitial lung diseases (ILD) constitute a group of entities characterized by inflammation and\u002For fibrosis of the lung parenchyma.\n\nIn recent years, with the advent of new diagnostic tools and therapeutic options, multidisciplinary evaluation is essential, since it optimizes the interpretation of each case and the quality of care for these pathologies Consensus for the identification and management of ILD associated with SSc (ILD-SSc) is the only guideline published at present. In the others autoimmune ILD (Ai-ILD), screening, diagnosis, treatment and follow-up strategies are usually performed according to the criteria of the treating medical team. Guidelines regarding the follow-up and indication of immunosuppressive and antifibrotic treatment are lacking. Many questions on the horizon of the Ai-ILD should be answered as better quality evidence emerges from studies with a greater number of patients and better methodological design.",[25],[133,58,134,59,135],"connective tissue disease","rheumatoid arthritis","interstitial penumonia with autoimmune features","2022-05-03",{"date":138,"type":30},"2022-05-06",{"date":140,"type":30},"2022-04-10",{"date":142,"type":20},"2027-10",{"name":144,"class":145},"EPIMAR registry","NETWORK"]